Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
News Jan 21, 2016
Agilent Technologies Inc. has announced an extension to its longstanding agreement with PerkinElmer, which supplies chips for Agilent's popular 2100 Bioanalyzer system.
Since its introduction in 1999, the 2100 Bioanalyzer system has become an integral part of molecular biology laboratories around the world. It is used in DNA sequencing, gene expression, DNA fragment analysis, quality control for protein-based drugs, and other applications.
"This agreement ensures that, for years to come, molecular biologists can continue to depend on the sample quality and high-fidelity data they obtain with the Agilent 2100 Bioanalyzer system," said Dr. Knut Wintergerst, marketing and support manager for microfluidics at Agilent.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.